Moderna, Inc. (MRNA) FY2026 YTD Q2 P&L / Income Statement

Moderna, Inc. (MRNA) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenue

534,000,000 US dollars

Cost of sales

1,048,000,000 US dollars

Gross profit (calculated)

negative 514,000,000 US dollars

Operating expenses (calculated)

1,689,000,000 US dollars

Loss from operations

negative 2,203,000,000 US dollars

Other income (expense), net (calculated)

102,000,000 US dollars

Loss before income taxes

negative 2,101,000,000 US dollars

Provision for income taxes

24,000,000 US dollars

Net loss

negative 2,125,000,000 US dollars

Other revenue

88,000,000 US dollars

Net product sales - UNITED STATES

143,000,000 US dollars

Net product sales - Rest of world

48,000,000 US dollars

Net product sales - Europe

255,000,000 US dollars

Research and development

1,300,000,000 US dollars

Selling, general and administrative

389,000,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.